Use of inpatient palliative care in metastatic testicular cancer patients undergoing critical care therapy : insights from the national inpatient sample

Article

CANO GARCIA, Cristina | INCESU, Reha-Baris | BARLETTA, Francesco | MORRA, Simone | SCHEIPNER, Lukas | BAUDO, Andrea | TAPPERO, Stefano | PICCINELLI, Mattia Luca | TIAN, Zhe | SAAD, Fred | SHARIAT, Shahrokh F. | TERRONE, Carlo | DE COBELLI, Ottavio | CARMIGNANI, Luca | AHYAI, Sascha | LONGO, Nicola | TILKI, Derya | BRIGANTI, Alberto | BANEK, Severine | KLUTH, Luis A. | CHUN, Felix K. H. | KARAKIEWICZ, Pierre I.

To test for rates of inpatient palliative care (IPC) in metastatic testicular cancer patients receiving critical care therapy (CCT). Within the Nationwide Inpatient Sample (NIS) database (2008–2019), we tabulated IPC rates in metastatic testicular cancer patients receiving CCT, namely invasive mechanical ventilation (IMV), percutaneous endoscopic gastrostomy tube (PEG), dialysis for acute kidney failure (AKF), total parenteral nutrition (TPN) or tracheostomy. Univariable and multivariable logistic regression models addressing IPC were fitted. Of 420 metastatic testicular cancer patients undergoing CCT, 70 (17%) received IPC. Between 2008 and 2019, the rates of IPC among metastatic testicular cancer patients undergoing CCT increased from 5 to 19%, with the highest rate of 30% in 2018 (EAPC: + 9.5%; 95% CI + 4.7 to + 15.2%; p = 0.005). IPC patients were older (35 vs. 31 years, p = 0.01), more frequently had do not resuscitate (DNR) status (34 vs. 4%, p < 0.001), more frequently exhibited brain metastases (29 vs. 17%, p = 0.03), were more frequently treated with IMV (76 vs. 53%, p < 0.001) and exhibited higher rate of inpatient mortality (74 vs. 29%, p < 0.001). In multivariable analyses, DNR status (OR 10.23, p < 0.001) and African American race/ethnicity (OR 4.69, p = 0.003) were identified as independent predictors of higher IPC use. We observed a significant increase in rates of IPC use in metastatic testicular cancer patients receiving CCT, rising from 5 to 19% between 2008 and 2019. However, this rates remain lower compared to metastatic lung cancer patients, indicating the need for further awareness among clinicians treating metastatic testicular cancer. The increase in IPC rates for metastatic testicular cancer patients receiving CCT indicates a need for ongoing education and awareness among healthcare providers. This could enhance the integration of IPC in the treatment of advanced cancer, potentially improving quality of life and care outcomes for survivors.

http://dx.doi.org/10.1038/s41598-024-83545-7

Voir la revue «Scientific reports, 15»

Autres numéros de la revue «Scientific reports»

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Gestion